Celldex drops in after-hours trading on phase 2 barzolvolimab results
Seeking Alpha ·
Celldex ( CLDX ) is down ~6% in after-hours trading Tuesday after phase 2 results for barzolvolimab for the chronic skin disease prurigo nodularis missed primary and secondary goals. The p ercentage of patients with at least a 4-point improvement in WI-NRS, the
AI 시장 분석
Celldex Therapeutics' (CLDX) Phase 2 clinical trial for the chronic skin disease treatment barzolvolimab failed to meet its primary and secondary efficacy endpoints. Following this news, the stock plummeted by about 6% in after-hours trading, reflecting investor disappointment. As uncertainty grows regarding the future success of the new drug pipeline, investment sentiment across the biotech sector is dampening.
하락 영향
- Biotech — Celldex's Phase 2 trial failure for barzolvolimab dashed expectations for core pipeline drug development, causing the stock to plunge by 6%.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 53% · Bearish (Short) 47%
270 participants
Related News
- Wistron Celebrates Grand Opening of First U.S. Smart Factory Marking Milestone in Global Smart Manufacturing Strategy
- Warren Buffett Reveals He Was Behind Berkshire's Decision to Invest in Alphabet
- Fantastic News for Netflix Stock Investors!
- PRE-MARKET AUSTRALIAN, JAPANESE & SOUTH KOREAN STOCK NEWS: Samsung Electronics (005930 KS) reportedly began construction of its hybrid bonding mass-production line at its Pyeongtaek P5 facility
- Hancock Whitney outlines 2026 outlook with One Florida, including 8%-9% net interest income growth
- "AI 패권 굳힌다" 엔비디아, 차세대 ’베라 루빈’ 본격 양산…AMD·빅테크 총공세 맞불
